Precision BioSciences (DTIL) Competitors $4.57 -0.24 (-4.99%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$4.68 +0.11 (+2.52%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL vs. DSGN, LIMN, VTYX, RAPT, MDWD, TLSA, ELDN, DMAC, YMAB, and NLTXShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Design Therapeutics (DSGN), Liminatus Pharma (LIMN), Ventyx Biosciences (VTYX), Rapt Therapeutics (RAPT), MediWound (MDWD), Tiziana Life Sciences (TLSA), Eledon Pharmaceuticals (ELDN), DiaMedica Therapeutics (DMAC), Y-mAbs Therapeutics (YMAB), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Its Competitors Design Therapeutics Liminatus Pharma Ventyx Biosciences Rapt Therapeutics MediWound Tiziana Life Sciences Eledon Pharmaceuticals DiaMedica Therapeutics Y-mAbs Therapeutics Neoleukin Therapeutics Precision BioSciences (NASDAQ:DTIL) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation. Do analysts rate DTIL or DSGN? Precision BioSciences currently has a consensus target price of $47.00, indicating a potential upside of 928.45%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts plainly believe Precision BioSciences is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is DTIL or DSGN more profitable? Design Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Design Therapeutics' return on equity of -22.85% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences-42.99% -69.26% -29.30% Design Therapeutics N/A -22.85%-22.02% Do insiders & institutionals believe in DTIL or DSGN? 38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 4.5% of Precision BioSciences shares are held by company insiders. Comparatively, 31.2% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher earnings & valuation, DTIL or DSGN? Precision BioSciences has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$68.70M0.74$7.17M-$2.01-2.27Design TherapeuticsN/AN/A-$49.59M-$0.99-4.01 Which has more risk & volatility, DTIL or DSGN? Precision BioSciences has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Does the media prefer DTIL or DSGN? In the previous week, Precision BioSciences had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 6 mentions for Precision BioSciences and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.00 beat Precision BioSciences' score of -0.57 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDesign Therapeutics beats Precision BioSciences on 8 of the 15 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.33M$2.98B$5.48B$9.56BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-2.2717.9729.9325.14Price / Sales0.74179.55375.2276.13Price / CashN/A41.8335.9458.58Price / Book0.677.238.105.59Net Income$7.17M-$54.43M$3.26B$265.48M7 Day Performance-1.08%0.22%0.68%1.22%1 Month Performance1.11%5.59%2.45%0.39%1 Year Performance-45.98%9.98%27.72%23.47% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.2339 of 5 stars$4.57-5.0%$47.00+928.4%-46.8%$53.33M$68.70M-2.27200News CoverageGap DownDSGNDesign Therapeutics0.2195 of 5 stars$4.04+0.5%$4.00-1.0%-2.7%$228.21MN/A-4.0840News CoverageEarnings ReportLIMNLiminatus PharmaN/A$8.08-7.2%N/AN/A$226.59MN/A0.00N/AVTYXVentyx Biosciences2.5791 of 5 stars$3.04-4.4%$10.00+228.9%+20.4%$226.29MN/A-1.7430News CoverageEarnings ReportUpcoming EarningsRAPTRapt Therapeutics4.1478 of 5 stars$12.67-4.8%$21.67+71.0%-46.8%$220.09MN/A-0.6680MDWDMediWound2.1759 of 5 stars$19.93-2.0%$32.25+61.8%+14.9%$219.72M$20.22M-9.5480Upcoming EarningsTLSATiziana Life Sciences0.2821 of 5 stars$1.95+4.8%N/A+49.3%$217.34MN/A0.008ELDNEledon Pharmaceuticals1.6755 of 5 stars$3.23-10.8%$10.00+209.6%+5.4%$216.77MN/A-1.5410Gap DownHigh Trading VolumeDMACDiaMedica Therapeutics1.4397 of 5 stars$5.06+0.2%$10.75+112.5%+48.3%$216.56MN/A-7.9120Gap UpYMABY-mAbs Therapeutics2.2872 of 5 stars$4.88+2.3%$15.60+219.7%-22.5%$216M$87.68M-7.63150Trending NewsUpcoming EarningsAnalyst DowngradeNLTXNeoleukin TherapeuticsN/A$22.72-0.4%N/A-43.8%$213.52MN/A-7.3190 Related Companies and Tools Related Companies Design Therapeutics Alternatives Liminatus Pharma Alternatives Ventyx Biosciences Alternatives Rapt Therapeutics Alternatives MediWound Alternatives Tiziana Life Sciences Alternatives Eledon Pharmaceuticals Alternatives DiaMedica Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Neoleukin Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DTIL) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DTIL Stock Alerts